Exicure Announces Appointment of James Sulat to Board of Directors
Exicure, Inc. (NASDAQ: XCUR) has appointed James Sulat to its Board of Directors, bringing extensive biopharmaceutical experience. Sulat has held leadership roles at various firms and currently serves on the boards of Valneva SE and Arch Therapeutics. His background in business development and finance is expected to support Exicure's growth. Additionally, Jay Venkatesan has resigned from the Board, effective December 29, 2020. The company focuses on gene regulatory therapies targeting cancer and genetic disorders using its proprietary SNA™ technology, with its lead program in a Phase 1b/2 trial.
- Appointment of James Sulat expected to enhance strategic direction due to his extensive biopharmaceutical experience.
- Sulat's background in finance and business development could support future growth and innovation for Exicure.
- Departure of Jay Venkatesan may create gaps in board continuity.
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointment of James Sulat to its Board of Directors.
James “Jim” Sulat joins Exicure after decades of experience advising and leading biopharmaceutical companies, including serving in the roles of President, Chief Executive Officer and Chief Financial Officer at various companies. Mr. Sulat currently serves on the boards of directors of Valneva SE and Arch Therapeutics and previously served on the boards of directors of other companies including AMAG Pharmaceuticals, Momenta Pharmaceuticals and Tolero Pharmaceuticals. Mr. Sulat served in several roles at Memory Pharmaceuticals from 2005 to 2009, a biopharmaceutical company focused on developing innovative drugs for the treatment of debilitating CNS disorders, which was acquired by Roche. Mr. Sulat holds a Bachelor of Science in Administrative Sciences from Yale University and a Master of Business Administration and a Master of Science in Health Services Administration from Stanford University.
“We are pleased to welcome Jim to our board. His extensive biopharmaceutical experience in business development, finance and building companies will be an asset to our Board and beneficial to Exicure’s future growth," said Timothy P. Walbert, Chairman of Exicure’s Board of Directors.
Exicure also announced today that Jay Venkatesan has stepped down from the Board of Directors, effective December 29, 2020.
“We would like to thank Jay for his tremendous support and guidance during the early formation and growth of Exicure,” said Dr. Giljohann, Exicure’s Chief Executive Officer.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. We believe Exicure's proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure's lead program is in a Phase1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL. www.exicuretx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005247/en/
FAQ
Who is James Sulat and what is his role at Exicure?
What impact does James Sulat’s appointment have on Exicure?
Why did Jay Venkatesan step down from Exicure’s Board?
What is the current focus of Exicure, Inc.?
What is the status of Exicure's lead program?
